Member Info for daveycaferacer

Over-allotment fully taken as expected, demonstrating significant confidence in the Company

https://www.slaterinvestments.com/financial_posts/commentary-slater-recovery-fund-annual-report-for-the-year-to-30th-november-2019/

"Hutchison China MediTech (HCM) had its best ever news in the clinic in June 2019 with spectacular phase 3 results from Surufatinib, leading to the early ending of the trial because they were so strong. Despite this news, the shares have drifted down resulting in a -1.60% detraction. This divergent performance was due to the very poorly handled reduction in the stake of parent company Hutchison Health to 49.9%. The turbulence in Hong Kong was a further factor, causing float plans to be aborted. In late September 2019 HCM gave further details on the Surufatinib results. These showed 9.3 months of progression free survival versus 3.8 months in the placebo arm, though there were also more frequent complications in treated versus untreated patients. One broker’s valuation assigned $11 per ADR to Surufatinib as it is wholly owned and seems likely to command a very high royalty if HCM chooses to out-license it. The highlight from a further raft of positive news flow in October and November 2019 was that Elunate, HCM’s anticancer drug for advanced colorectal cancer, will be eligible for reimbursement in China. The company is expected to become heavily profitable from 2023."

https://www.thetimes.co.uk/article/coronavirus-fears-grip-global-markets-ww2fnzz8k#top

n Hong Kong on Friday, Christian Hogg was wondering what to tell his 5,000 staff in China. The chief executive of drug-maker Hutchison China Meditech had been hoping to reopen his factory near Shanghai tomorrow after the Chinese New Year holiday. The coronavirus outbreak put paid to that.

“We’ll evaluate what we’re going to do at the end of this week, but our factories are going to have to start producing,” said Hogg, working from his home in Hong Kong after the territory closed off most travel to China.

Hogg, 54, is one of many bosses forced to take drastic action after the number of reported cases of the coronavirus topped 12,000. Russia has closed its border with China. Airlines have stopped all flights to and from China. Starbucks, McDonald’s and H&M have closed stores in the country; Wuhan, the city at the centre of the epidemic, has been described as a “ghost town”. The virus has also torn through global markets as investors, wary of a “Black Swan” event that could bring the long asset-price boom crashing down, have run for cover.

https://twitter.com/LoncarFunds/status/1222167444837429248?s=20

wonderful to see a Savolitinib indication progress line right up to the right hand side of the chart for Exon14 del.

The very large pipeline was updated yesterday on the Company's website, a pipeline many larger Biopharma's would be happy to have!

https://www.chi-med.com/innovation-platform/our-pipeline/

Rather ridiculously we are now back to the share price we were in August 2017, despite all the progress and all the wonderful things the Company has delivered. I do not understand the current valuation.

https://www.tipranks.com/stocks/hcm/price-target

5-star analyst John Newman from Canaccord Genuity maintained a Buy on $HCM

tipranks.com/analysts/john-...

https://www.trinitydelta.org/research-notes/2020-set-to-be-the-breakthrough-year/

A new research note has been posted by Trinity Delta today

gs, Christian mentioned possible M & A activity, disposal of non-core assets and a possible acquisition of a large molecule asset or player at the JPM meeting. Also noted on slide 33 of the latest Corporate Presentation. I continue to Buy ;o-)

Agreed Jatw but some form of M & A, probably A is on the cards, maybe a large molecule asset. CP disposals have also been mooted. I am also not sure whatever happened to the 2nd tranche of property/land compensation.

Having had in excess of $300m in mid 2019 there must surely be another reason for raising more now. I can only assume the mooted M & A means more is needed in the short term.

IC are always bullish on Chi Med, hopefully it will continue despite testing some Investors patience!

I still don't understand why a $110m placing wipes $500m off the mcap

6 months of recovery wiped out in 24 hours

I will however be buying more tomorrow

$110m raised but almost half a billion taken off the market cap. I don't quite see the market logic here.

Indeed turramurra and I only ever buy, never sell, so not an issue ;o-)

If the Offering timetable plays out like the one in Oct 2017 we can expect an RNS announcement re: Underwriters taking the over-allotment tomorrow (hopefully) and the closure of the Offering on Monday.

If it also plays out like last time this could go up significantly in the following days and weeks.